| If you have trouble viewing the newsletter, please click here. |
|
Dear ESOP Members, Welcome to our new issue in March, heralding the arrival of spring. In this issue we have included articles about ESOP board meeting and ESOP Working Group's meetings held during cold winter days in Hamburg and �ESOP eligibility in EMA'. . Also ESOP would like to remind you "EJOP is waiting for your contributions to be useful to a wider audience" We wish you enjoyable readings� Eda Gedikoglu Chair of Publication |
|
"ESOP conference for Quality in Oncology" |
|
|
The next ESOP conference for Quality in Oncology will take place in the �ESTRO office� in Brussels, Belgium from 16th to 17th of March 2018. |
|
|
ESOP Board Meeting and Working groups |
|
|
ESOP Board Meeting
The ESOP board meeting was held in Hamburg on January 26, 2018, just like every year. Board members discussed all the works planned to be done in the forthcoming period and determined the topics for the delegate meeting to be held in Brussels. ESOP Working Groups
ESOP Education, Quapos ,EPIC working group members came together on24-25 January in Hamburg. Intensive work has been done, working groups have made annual plans. They set out what to do next and the roadmap to follow.
|
|
|
|
|
NZW Europe � ESOP SHORT LECTURE SESSION This year ESOP session took place in NZW which was held in Hamburg on 26-28 January 2018, as previous years. The opening session was made by ESOP president Klaus Meier. Then, current and interesting presentations were made. ERQCC-a multiprofessional approach by Prof.Dr. Riccardo A.Audisio, UK; Oncology Medicine for Pediatrics The SIOPe / ESOP Collaboration by Sherif Kamal, Egypt and Svetlana Griskjane, Latvia; Biosimilars Acceptance: Role of Pharmacists by Prof. Alain Astier, France; Quapos 6, New Edition of Quality Standards in Oncology by Kristjan Kongi, Estonia; Challenges in the Exposure -Response Assessment of Antibody-Based Oncology Agents, USA were presantions made. |
|
|
|
ESOP eligibility in EMA On December 15, 2017 ESOP received from Juan Garcia Burgos / Head of Public Engagement Department in EMA/ the result of re-evaluation of eligibility � �European Society of Oncology Pharmacy continues to comply with the EMA eligibility requirements and will therefore remain on the list of EMA eligible organisations and be contacted for involvement in EMA activities as appropriate The European Medicines Agency (EMA) engages with a network of over twenty eligible organisations ensuring that the needs and concerns of a wide range of healthcare professionals across Europe are represented via direct contact with the EMA. These organisations are not-for-profit, in most cases have a European Union-wide mandate, and include:
Eligible organisations receive targeted EMA communications and consultations and frequently assist in the identification of experts for product-specific matters. By Velina Grigorova, Liaison Commissioner for EMA |
|
ECCO and ESOP European Cancer Organisation (ECCO) is the multiprofessional and interdisciplinary organisation that connects and responds to all stakeholders in oncology Europe-wide. ECCO upholds the right of all European cancer patients to the best possible treatment and care, promoting interaction between all organisations involved in cancer at European level. |
|
|
ESOP has participated and been acting as part of ECCO in the multiprofessional team. These studies include studies that our colleagues can use in their daily working lives and that can contribute scientifically to them. Expert members of ESOP Michael Höckel (Prostate) , D; Hannelore Kreckel (Melanoma) D; Mirjam Crul (Colorectal CA), NL; Marko Skelin (Breast), HR; Irena Netikova (CZ) have worked extensively as ESOP representatives and offer contributions.
ESOP would like to inform you of some articles published by ECCO. Please find attached the pdf of the manuscript and relevant links to share the articles as follows:
doi.org/10.1016/j.critrevonc.2017.12.019 |
|
|
The European Journal of Oncology Pharmacy continues to include scientific topics in oncology pharmacy!!! |
|
|
The European Journal of Oncology Pharmacy (EJOP) continues to include scientific topics in oncology pharmacy!!! EJOP is a peer-reviewed pharmaceutical journal in the field of cancer treatment. The journal encompasses all the recent issues related to the role of pharmacists in the prevention and treatment of cancers under its scope. This includes basic and applied researches on the synthesis or extraction, compounding, analysis, stability, pharmacology, side-effects, and clinical use of anticancer drugs and adjuvants therapies such as antiemetic, analgesic, or complementary medicines. Now Open for Manuscript Submissions EJOP now seeks top-quality articles from the global research community which will aid in achieving high impact factor and largest diffusion. Authors are encouraged to share their ideas and valuable research outcomes through this Journal and provide the global readers updated and most important information in the mode of original articles, review articles, case reports, and short communications. Benefits to Publishing in European Journal of Oncology Pharmacy!
More info at www.editorialmanager.com/EJOP |
|
 |
European Society of Oncology Pharmacy |
|
| If you don't want to recieve any further ESOP Newsletters, please click to unsubscribe. |